CAS 677017-23-1

Berubicin

Description:

Berubicin is an anthracycline antibiotic that is primarily investigated for its potential use in cancer therapy, particularly in treating various types of tumors. It is derived from the natural product doxorubicin, with modifications that aim to enhance its efficacy and reduce side effects. Berubicin exhibits a mechanism of action that involves intercalating into DNA, thereby disrupting the replication process and inducing apoptosis in rapidly dividing cancer cells. Its chemical structure includes a tetracyclic ring system characteristic of anthracyclines, which contributes to its biological activity. The compound is known for its ability to generate reactive oxygen species, further contributing to its cytotoxic effects. Berubicin has been studied in clinical trials, and while it shows promise, its safety profile and therapeutic effectiveness continue to be evaluated. As with many chemotherapeutic agents, potential side effects may include cardiotoxicity, which is a common concern with anthracyclines. Overall, Berubicin represents a significant area of research in the ongoing quest for effective cancer treatments.

Berubicin

CAS: 677017-23-1

Formula: C₃₄H₃₅NO₁₁

Molecular weight: 633.65

Ref: 4Z-B-256001

4'O-Benzyl Doxorubicin

Controlled Product

CAS: 677017-23-1

Formula: C₃₄H₃₅NO₁₁

Color and Shape: Neat

Molecular weight: 633.642

Ref: TR-B788120

Berubicin

CAS: 677017-23-1

Berubicin is an anthracycline-based chemotherapeutic agent, which is a semi-synthetic derivative sourced primarily from the bacterium Streptomyces peucetius. It operates by intercalating into DNA strands, disrupting the replication and transcription processes, which ultimately induces apoptosis in rapidly dividing tumor cells.

Formula: C₃₄H₃₅NO₁₁

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 633.6 g/mol

Ref: 3D-BB178714